


Daniel M. Bradbury
BioBrit, LLC / Equillium, Inc.
2223 Avenida de la Playa
Suite 108
La Jolla CA 92037

Email: dan@biobrit.com
dbradbury@equilliumbio.com
Mobile: (858) 344-6124



Life sciences executive with over 35 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value.

EXPERIENCE

Chief Executive Officer, Chairman and Co-Founder **Equillium, Inc. – www.equilliumbio.com**

May 2017 – present

- Private US Biopharmaceutical Company focused on developing first-in-class therapies to treat severe autoimmune disorders with high unmet medical need

Managing Member **BioBrit, LLC – www.biobrit.com**

September 2012 – present

- Life Sciences Consulting and Investment Firm

President and Chief Executive Officer and Director **Amylin Pharmaceuticals, Inc. (1994-2012)**

March 2007 – August 2012

- Public US Biopharmaceutical Company focused on developing medicines for the treatment of metabolic diseases – diabetes, obesity and lipodystrophy
- Led process resulting in the sale of Amylin to Bristol-Myers Squibb for \$7B
- Led company through a highly complex regulatory process and gained approval of and launched BYDUREON® in USA
- Managed company to positive operating cash flow for the first time in its 24-year history in 2011
- Sued and subsequently settled with Eli Lilly resulting in the return of global rights to exenatide
- Managed company through a complicated proxy challenge from Carl Icahn and Eastbourne Capital
- Drove a global development and commercialization agreement with Takeda for obesity assets
- Restructured Amylin after an FDA safety alert on BYETTA led to a significant decline in revenues

President and Chief Operating Officer and Director **Amylin Pharmaceuticals, Inc.**

June 2006 – March 2007

- Responsible to CEO for Research and Development, Regulatory Affairs, Corporate Strategy, Alliance management and Business Development
- Integral in financial strategy involving raising >\$2 billion through sale of equity and debt since 1998

Chief Operating Officer **Amylin Pharmaceuticals, Inc.**

June 2003 – June 2006

- Responsible to CEO for Research and Development, Regulatory Affairs and Business Development
- Gained approval of BYETTA® and SYMLIN® in US and BYETTA® in Europe
- BYETTA® approved in over 90 countries

Executive Vice President

Amylin Pharmaceuticals, Inc.

June 2000 – June 2003

- Responsible to CEO for Finance, Legal, Clinical Research, Discovery, Business Development, Strategic Planning, European Operations, Investor Relations and Corporate Communications
- Instrumental in the negotiation of the \$465M exenatide global development and commercialization agreement with Eli Lilly & Co.
- Lead executive responsible for finance strategy and resource allocation

Senior Vice President, Corporate Development

Amylin Pharmaceuticals, Inc.

March 1998 – June 2000

- Responsible to CEO for Business Development, Strategic Planning, Investor Relations, Corporate Communications and Marketing
- Negotiated sale of Product Development Division to Magellan Labs (now Cardinal)
- Negotiated feasibility and development collaborations with multiple drug delivery companies
- In-licensed multiple patents to enhance patent portfolio of development programs

Vice President, Marketing

Amylin Pharmaceuticals, Inc.

June 1995 – March 1998

- Commercial Liaison Officer Amylin/Johnson & Johnson collaboration and Co-chair Joint Commercialization Committee
- Successfully managed global coordination of SYMLIN™ commercialization planning with Johnson & Johnson commercial teams
- Built global Strategic Marketing Team with national expertise in US and major European markets - team located in San Diego, New Jersey, Oxford (UK), Paris (France) and Dusseldorf (Germany)
- Provided commercial assessment of in-license candidates – AC2993 (exendin-4) & HMR deals

Director, Marketing Amylin Pharmaceuticals

Amylin Europe, UK

July 1994 – June 1995

- Presented market opportunity for Amylin agonist program to multiple pharmaceutical companies as part of Corporate partnership strategy
- Negotiated commercialization relationship in worldwide SYMLIN™ collaboration agreement with Johnson & Johnson
- Implemented worldwide SYMLIN™ medical communications program

Assoc. Director Anti-Infectives, Worldwide Strategic Product Development

SmithKline Beecham Pharmaceuticals, UK (1984-1994)

February 1991 – July 1994

- Global Pharmaceutical Company focused on developing and commercializing medicines and vaccines
- Focused R&D teams on the key competitive issues relating to the Global antiviral market and negotiated a revised development plan leading to accelerated FAMVIR™ launches
- Initiated DENAVIR™ OTC switch strategy
- Provided strategic and tactical support for successful UK FAMVIR™ launch in January 1994 and US FAMVIR™ launch in July 1994 (FAMVIR™ sold by SB to Novartis for \$1.63BN in August 2000)
- Authored Global Anti-Infectives/Vaccines Therapeutic 15-year strategic plan

Product Group Manager, International Area Marketing

SmithKline Beecham Pharmaceuticals, UK

June 1990 – February 1991

- Successfully initiated Area Marketing program to establish SB in the hospital injectable antibiotics market, e.g. Launched TIMENTIN™ & IV AUGMENTIN™ in Indonesia, relaunched IV AUGMENTIN™ in Saudi Arabia and launched TIMENTIN™ & IV AUGMENTIN™ in Mexico

Area Manager Gulf States, International Division

December 1988 – June 1990

Beecham Pharmaceuticals, Sharjah, UAE

- Managed Area Office. Responsible for two sales forces and six distributors across five markets (Bahrain, Kuwait, Oman, Qatar, UAE). Responsible for Area Profit - 1989 Area Gross Profit growth rate 23%
- Managed area integration of Beecham and SK&F teams

Marketing Supervisor Middle East, International Division

October 1987 – December 1988

Beecham Pharmaceuticals, UK

- Effectively coordinated Middle East promotional activity and conducted numerous representative training courses for Middle East AUGMENTIN™ and BACTROBAN™ launches

International Trainee, International Division

September 1984 – October 1987

Beecham Pharmaceuticals, UK

- Marketing Executive, Marketing and Services Department
- Medical Representative, Beecham Research Laboratories, UK Division
- Area Assistant, International Division

Pre-registration Pharmacist

September 1983 – September 1984

Glaxo Group Research & Northwick Park Hospital, UK

EDUCATION

1983 Nottingham University, UK

- B.Pharm (Hons) Upper Second
- Registered UK Pharmacist 1984 – 2011

1985 Harrow and Ealing Colleges of Higher Education, UK

- Postgraduate Diploma in Management Studies (DMS)
- Diploma of the Chartered Institute of Marketing (DCIM)

1994 INSEAD, European Institute of Business Administration, France

- International Executive Program

2004 University of California, Los Angeles

- Director Certification Program

HONORS AND AWARDS

- American Diabetes Association's Father of the Year – San Diego Chapter (2011)
- E&Y Entrepreneur of the Year Finalist (2012)
- Corporate Directors Forum Director of the Year Award – Enhancing Economic Value (2012)

BOARDS AND COMMITTEES

Public Boards:

illumina, Inc. (2004 – 2017) / www.illumina.com (NASDAQ: ILMN)

- Independent Director
- Audit Committee (Chair: 2005 – 2010)
- Compensation Committee
- Nominating and Governance Committee (Chair: 2013 – 2017)

Novacea, Inc. (2005 – 2009) / (NASDAQ: NOVC) – merged with Transcept Pharmaceuticals Inc.

- Director
- Compensation Committee (Chair)
- Nominating and Corporate Governance Committee

Amylin Pharmaceuticals, Inc. (2006 – 2012) / (NASDAQ: AMLN)

Acquired by Bristol-Myers Squibb for \$7B

- Director
- Finance and Risk Committee

Geron Corporation (2012 – present) / www.geron.com (NASDAQ: GERN)

- Independent Director
- Audit Committee (2012 – present)
- Nominating and Governance Committee (2015 – present)

Corcept Therapeutics, Inc. (2012 – present) / www.corcept.com (NASDAQ: CORT)

- Independent Director
- Compensation Committee (2013 – present)
- Nominating and Governance Committee (2016 – present)

BioMed Realty Trust, Inc. (2013 – 2016) / www.biomedrealty.com (NYSE: BMR)

Acquired by Blackstone Real Estate Partners VIII L.P. for \$8B

- Lead Independent Director
- Compensation Committee
- Nominating and Governance Committee (Chair)

Biocon Limited (2013 – present) / www.biocon.com (NSE: BIOCON)

- Independent Director
- Audit and Risk Committee (2013 – present)
- Stakeholders Relationship (Chair: 2015 – present)
- Nomination and Remuneration Committee (2013 – 2015)

Syngene International Limited (2015 – 2016) / <http://www.syngeneintl.com> (NSE: SYNGENE)

- Independent Director
- Nomination and Remuneration Committee

Intercept Pharmaceuticals, Inc. (2016 – present) / www.interceptpharma.com (NASDAQ: ICPT)

- Independent Director
- Audit Committee
- Nominating and Governance Committee

Private Boards:

Peninsula Pharmaceuticals, Inc. (2003 – 2005) – acquired by J&J for \$245M

- Director

Cerexa, Inc. (2005 – 2006) – acquired by Forest Laboratories for \$494M

- Director
- Compensation Committee (Chair)

Castle Biosciences, Inc. (2012 – present) / www.castlebiosciences.com

- Chairman of the Board
- Compensation Committee

Microdermis Corporation (2013 – 2018) / www.microdermis.com

- Director
- Audit Committee (Chair)

Freedom Meditech (2013 – 2017) / www.freedom-meditech.com

- Chairman of the Board

DiaVacs, Inc. (2013 – present) / www.diavacs.com

- Chairman of the Board

ProSciento, Inc. (2013 – present) / www.prosciento.com

**formerly Profil Institute for Clinical Research*

- Director

Troia Therapeutics, Inc. (2014 – 2017)

- Chairman of the Board

Liquid Grids, Inc. (2014 – present) / www.liquidgrids.com

- Chairman of the Board

Sensulin, LLC (2014 – present) / www.sensulin.com

- Chairman of the Board

Renova Therapeutics (2014 – present) / www.renovatherapeutics.com

- Director
- Compensation Committee (Chair)

Thesan Pharmaceuticals, Inc. (2016 – 2017) / www.thesanpharma.com

- Chairman of the Board

Equillium, Inc. (2017 – present) / www.equilliumbio.com

- Chairman of the Board

NeuroVia, Inc. (2017 – present) / www.neurovia-inc.com

- Chairman of the Board

Biolinq, Inc. (2017 – present) / www.bioliq.me

- Chairman of the Board

Advisory Boards:

EGS PARTNERS \$100mm Biomedical Investment Fund Advisory Board (2000 – 2009)

- Advisor

RAND Health Board of Advisors (2008 – 2013) / www.rand.org

- Advisor

University of Miami's Innovation Corporate Advisory Council (2009 – 2014)

- Advisor

Patricia Industries (a part of Investor AB) (2010 – 2017) / <http://www.patriciaindustries.com>

**formerly Investor Growth Capital*

- Advisor

BioMed Ventures Advisory Committee (2011 – present) / www.biomedrealty.com

- Advisor

Pharming Group N.V. Commercial Advisory Board (2017 – present) / www.pharming.com

- Chairman of the Board

ProLynx, LLC Advisory Board (2017 – present) / www.prolynxllc.com

- Advisor

Arctic Aurora Life Science Advisory Board (2017 – present) /

<https://www.arctic.com/afm/department/our-funds/#arctic-aurora-lifescience>

- Advisor

Non-Profit Boards:

Keck Graduate Institute (a Claremont College) (2006 – present) / www.kgi.edu

- Member of the Board of Trustees
- Budget and Finance Committee (2007 – present)
- Audit and Risk Committee (2008 – 2012 / 2015 – present)
- Advancement Committee (2006 – 2009 / 2012 – 2015)
- Chairman of the KGI Advisory Council (2003 – 2006)

UCSD Rady School of Management (2006 – present) / www.rady.ucsd.edu

- Member of the Dean's Advisory Council

Pharmaceutical Research and Manufacturers of America (2007 – 2010) / www.phrma.org

- Director

BIOCOM (2007 – 2012) / www.biocom.org

- Director (Chair 2010)

Riecken Community Libraries (2014 – present) / www.riecken.org

- Director

ADCY5.org (2016 – present) / www.ADCY5.org

- Chairman of the Board

The San Diego Exploratory Foundation (SDEF) (2017 – present) / <https://awbgsandiego.com/about/>

- Member of the World Beach Games 2019 Committee